|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 331.70 USD | +0.79% |
|
+0.57% | +1.34% |
| 09/05 | Kennedy's health officials explored US ban of some widely used antidepressants, sources say | RE |
| 05/05 | Viridian eye disease drug surpasses expectations in late-stage trial; shares soar | RE |
| Capitalization | 179B 152B 139B 131B 245B 16,907B 247B 1,651B 644B 8,121B 672B 658B 28,038B | P/E ratio 2026 * |
21.3x | P/E ratio 2027 * | 19.5x |
|---|---|---|---|---|---|
| Enterprise value | 220B 187B 171B 162B 302B 20,801B 304B 2,031B 792B 9,992B 826B 809B 34,496B | EV / Sales 2026 * |
5.83x | EV / Sales 2027 * | 5.53x |
| Free-Float |
99.78% | Yield 2026 * |
3.04% | Yield 2027 * | 3.21% |
Last Transcript: Amgen Inc.
| 1 day | +0.79% | ||
| 1 week | +0.57% | ||
| Current month | -4.20% | ||
| 1 month | -6.72% | ||
| 3 months | -11.74% | ||
| 6 months | +3.59% | ||
| Current year | +1.34% |
| 1 week | 320.52 |  | 332.98 |
| 1 month | 320.52 | | 356.9 |
| Current year | 318.21 | | 391.29 |
| 1 year | 261.43 | | 391.29 |
| 3 years | 211.71 | | 391.29 |
| 5 years | 198.64 | | 391.29 |
| 10 years | 133.64 | | 391.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 01/05/2012 |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 01/01/2020 |
Esteban Santos
COO | Chief Operating Officer | 59 | 25/07/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 01/01/2013 |
Tyler Jacks
BRD | Director/Board Member | 65 | 01/01/2012 |
Robert Eckert
BRD | Director/Board Member | 71 | 01/01/2012 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +5.34% | 3.71% | 27 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.79% | +0.57% | +24.76% | +41.49% | 179B | |
| -2.72% | -1.54% | +29.12% | +121.40% | 846B | |
| -0.53% | -2.58% | +43.51% | +37.42% | 533B | |
| -0.57% | -2.44% | +9.18% | +37.27% | 356B | |
| -0.94% | -0.97% | +22.40% | +11.18% | 324B | |
| +0.23% | -1.24% | +30.31% | +12.00% | 282B | |
| +0.05% | -2.19% | +24.69% | +21.29% | 278B | |
| -0.82% | -0.70% | +46.61% | -5.15% | 275B | |
| -1.76% | +4.42% | -34.66% | -49.15% | 203B | |
| -2.04% | -0.24% | +35.52% | +66.66% | 163B | |
| Average | -0.83% | -0.69% | +23.14% | +29.44% | 343.84B | |
| Weighted average by Cap. | -1.10% | -1.22% | +26.11% | +45.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.78B 32.1B 29.37B 27.72B 51.72B 3,568B 52.17B 348B 136B 1,714B 142B 139B 5,917B | 38.74B 32.92B 30.12B 28.43B 53.04B 3,659B 53.5B 357B 139B 1,758B 145B 142B 6,068B |
| Net income | 8.37B 7.11B 6.51B 6.14B 11.45B 790B 11.55B 77.17B 30.08B 380B 31.39B 30.73B 1,310B | 9.1B 7.73B 7.08B 6.68B 12.46B 860B 12.57B 83.95B 32.73B 413B 34.15B 33.43B 1,426B |
| Net Debt | 41.23B 35.03B 32.06B 30.26B 56.44B 3,894B 56.94B 380B 148B 1,870B 155B 151B 6,458B | 35.08B 29.81B 27.28B 25.75B 48.03B 3,313B 48.45B 324B 126B 1,592B 132B 129B 5,495B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/05/26 | 331.70 $ | +0.79% | 2,443,294 |
| 07/05/26 | 329.09 $ | -0.61% | 3,296,982 |
| 06/05/26 | 331.11 $ | +0.46% | 2,874,747 |
| 05/05/26 | 329.59 $ | +1.77% | 3,321,411 |
| 04/05/26 | 323.85 $ | -1.81% | 3,481,360 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition